mones in the regulation of insulin secre-tion in diabetic and nondiabetic humans.Am J Physiol Endocrinol Metab 287:E199– E206, 2004 21. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalizationof fasting hyperglycaemia by exogenousglucagon-like peptide 1 (7–38 amide) intype 2 (non-insulin-dependent) diabeticpatients. Diabetologia 36:741–744, 1993 22. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insu-lin sensitivity, and /H9252-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830, 2002 23. Go ¨ke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Go ¨ke B: Exendin-4 is a high potency agonist and truncated ex-endin-(9–39)-amide an antagonist at theglucagon-like peptide 1-(7–36)-amide re-ceptor of insulin-secreting /H9252-cells. J Biol Chem 268:19650–19655, 1993 24. Szayna M, Doyle ME, Betkey JA, Hollo-